Cargando…

The PARP Way to Epigenetic Changes

ADP-ribosylation, is a reversible post-translational modification implicated in major biological functions. Poly ADP-ribose polymerases (PARP) are specialized enzymes that catalyze the addition of ADP ribose units from “nicotinamide adenine dinucleotide-donor molecules” to their target substrates. T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ummarino, Simone, Hausman, Clinton, Di Ruscio, Annalisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003872/ https://www.ncbi.nlm.nih.gov/pubmed/33804735 http://dx.doi.org/10.3390/genes12030446

Ejemplares similares

The Bright and Dark Side of DNA Methylation: A Matter of Balance
por: Borchiellini, Marta, et al.
Publicado: (2019)

Application of Induced Pluripotent Stem Cell Technology to the Study of Hematological Diseases
por: Li, Mailin, et al.
Publicado: (2017)

NAD Modulates DNA Methylation and Cell Differentiation
por: Ummarino, Simone, et al.
Publicado: (2021)

Epigenetic Insights on PARP-1 Activity in Cancer Therapy
por: Pinton, Giulia, et al.
Publicado: (2022)

Editorial: Interplay between epigenetic modifiers and transcription factors in driving cancer progression
por: Yang, Yongyong, et al.
Publicado: (2023)

Immunomodulatory Roles of PARP-1 and PARP-2: Impact on PARP-Centered Cancer Therapies
por: Yélamos, José, et al.
Publicado: (2020)

PARP Power: A Structural Perspective on PARP1, PARP2, and PARP3 in DNA Damage Repair and Nucleosome Remodelling
por: van Beek, Lotte, et al.
Publicado: (2021)

Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors
por: Chu, Yu-Yi, et al.
Publicado: (2022)

PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs
por: Wang, Luyao, et al.
Publicado: (2017)

Epigenetic Landscape in Pancreatic Ductal Adenocarcinoma: On the Way to Overcoming Drug Resistance?
por: Ciernikova, Sona, et al.
Publicado: (2020)

Epigenetic Features of Human Perinatal Stem Cells Redefine Their Stemness Potential
por: Gaggi, Giulia, et al.
Publicado: (2020)

Is There an Epigenetic Component Underlying the Resistance of Triple-Negative Breast Cancers to Parp Inhibitors?
por: Lovato, Amanda, et al.
Publicado: (2012)

New perspectives on epigenetic modifications and PARP inhibitor resistance in HR-deficient cancers
por: Bayley, Rachel, et al.
Publicado: (2023)

Mono-ADP-ribosylation by PARP10 and PARP14 in genome stability
por: Dhoonmoon, Ashna, et al.
Publicado: (2023)

New Insights into Mechanisms of Endocrine-Disrupting Chemicals in Thyroid Diseases: The Epigenetic Way
por: Pitto, Letizia, et al.
Publicado: (2020)

Reverse the Resistance to PARP Inhibitors
por: Kim, Yevgeniy, et al.
Publicado: (2017)

Mitochondrial Protection by PARP Inhibition
por: Gallyas Jr., Ferenc, et al.
Publicado: (2020)

Advances and perspectives of PARP inhibitors
por: Yi, Ming, et al.
Publicado: (2019)

Antifragility and Tinkering in Biology (and in Business) Flexibility Provides an Efficient Epigenetic Way to Manage Risk
por: Danchin, Antoine, et al.
Publicado: (2011)

Epigenetic Treatment of Urothelial Carcinoma Cells Sensitizes to Cisplatin Chemotherapy and PARP Inhibitor Treatment
por: Thy, Sophia, et al.
Publicado: (2021)

TASOR is a pseudo-PARP that directs HUSH complex assembly and epigenetic transposon control
por: Douse, Christopher H., et al.
Publicado: (2020)

PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives
por: Musacchio, Lucia, et al.
Publicado: (2020)

An update on PARP inhibitors for the treatment of cancer
por: Benafif, Sarah, et al.
Publicado: (2015)

Role of Biomarkers in the Development of PARP Inhibitors
por: Ganguly, Bratati, et al.
Publicado: (2016)

The Nucleolus and PARP1 in Cancer Biology
por: Engbrecht, Marina, et al.
Publicado: (2020)

PARP Inhibitors Resistance: Mechanisms and Perspectives
por: Giudice, Elena, et al.
Publicado: (2022)

PARP Inhibitors in Breast and Ovarian Cancer
por: Wang, Samuel S. Y., et al.
Publicado: (2023)

Advances in PARP Inhibitors for Prostate Cancer
por: Tisseverasinghe, Steven, et al.
Publicado: (2023)

Minding the gap: Unlockingthe therapeutic potentialof aptamers and making up for lost time
por: Di Ruscio, Annalisa, et al.
Publicado: (2022)

Epigenetic Changes Associated with Osteosarcoma: A Comprehensive Review
por: Twenhafel, Luke, et al.
Publicado: (2023)

Epigenetic changes in cancer
por: Esteller, Manel
Publicado: (2011)

Epigenetic changes in colorectal cancer
por: Jia, Yan, et al.
Publicado: (2013)

Nuclear PARPs and genome integrity
por: Azarm, Kameron, et al.
Publicado: (2020)

The Way to Malignant Transformation: Can Epigenetic Alterations Be Used to Diagnose Early-Stage Head and Neck Cancer?
por: Lai, Ting-Yu, et al.
Publicado: (2023)

The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors
por: Wu, Zhaozhen, et al.
Publicado: (2021)

Prostate cancer and PARP inhibitors: progress and challenges
por: Teyssonneau, Diego, et al.
Publicado: (2021)

PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?
por: Barcellini, Amelia, et al.
Publicado: (2021)

PARP Inhibitors and Haematological Malignancies—Friend or Foe?
por: Skelding, Kathryn A., et al.
Publicado: (2021)

PARP Inhibitors in Melanoma—An Expanding Therapeutic Option?
por: Chan, Wei Yen, et al.
Publicado: (2021)

PARP inhibitors in gastric cancer: beacon of hope
por: Wang, Yali, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tc27h2ca1ubrdc7na4oasen8v7